1887

Abstract

Resistance against macrolide antibiotics in is becoming non-negligible in terms of both appropriate therapy and diagnostic stewardship. Molecular methods have attractive features for the identification of as well as its resistance-associated mutations of 23S ribosomal RNA (rRNA).

The automated molecular diagnostic sytem can identify macrolide-resistant .

To assess the performance of an automated molecular diagnostic system, GENECUBE Mycoplasma, in the detection of macrolide resistance-associated mutations.

To evaluate whether the system can distinguish mutant from wild-type 23S rRNA, synthetic oligonucleotides mimicking known mutations (high-level macrolide resistance, mutation in positions 2063 and 2064; low-level macrolide resistance, mutation in position 2067) were assayed. To evaluate clinical oropharyngeal samples, purified nucleic acids were obtained from -positive samples by using the GENECUBE system from nine hospitals. After confirmation by re-evaluation of positivity, Sanger-based sequencing of 23S rRNA and mutant typing using GENECUBE Mycoplasma were performed.

The system reproducibly identified all synthetic oligonucleotides associated with high-level macrolide resistance. Detection errors were only observed for A2067G (in 2 of the 10 measurements). The point mutation in 23S rRNA was detected in 67 (26.9 %) of 249 confirmed -positive clinical samples. The mutations at positions 2063, 2064 and 2617 were observed in 65 (97.0 %), 2 (3.0 %) and 0 (0.0 %) of the 67 samples, respectively. The mutations at positions 2063 and 2064 were A2063G and A2064G, respectively. The results from mutant typing using GENECUBE Mycoplasma were in full agreement with the results from sequence-based typing.

GENECUBE Mycoplasma is a reliable test for the identification of clinically significant macrolide-resistant .

Funding
This study was supported by the:
  • Katsunori Yanagihara , TOYOBO Co., Ltd. , (Award None)
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001264
2020-11-03
2021-01-19
Loading full text...

Full text loading...

References

  1. Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol 2016; 7:974 [CrossRef][PubMed]
    [Google Scholar]
  2. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 2008; 52:348–350 [CrossRef][PubMed]
    [Google Scholar]
  3. Tanaka T, Oishi T, Miyata I, Wakabayashi S, Kono M et al. Macrolide-resistant Mycoplasma pneumoniae infection, Japan, 2008-2015. Emerg Infect Dis 2017; 23:1703–1706 [CrossRef][PubMed]
    [Google Scholar]
  4. Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front Microbiol 2016; 7:693 [CrossRef][PubMed]
    [Google Scholar]
  5. Yin YD, Wang R, Zhuo C, Wang H, Wang MG et al. Macrolide-resistant Mycoplasma pneumoniae prevalence and clinical aspects in adult patients with community-acquired pneumonia in China: a prospective multicenter surveillance study. J Thorac Dis 2017; 9:3774–3781 [CrossRef][PubMed]
    [Google Scholar]
  6. Zhao F, Liu G, Wu J, Cao B, Tao X et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother 2013; 57:1521–1523 [CrossRef][PubMed]
    [Google Scholar]
  7. Brown RJ, Macfarlane-Smith L, Phillips S, Chalker VJ. Detection of macrolide resistant Mycoplasma pneumoniae in England, September 2014 to September 2015. Euro Surveill 2015; 20:30078 [CrossRef][PubMed]
    [Google Scholar]
  8. Eshaghi A, Memari N, Tang P, Olsha R, Farrell DJ et al. Macrolide-resistant Mycoplasma pneumoniae in humans, Ontario, Canada, 2010-2011. Emerg Infect Dis 2013; 19: [CrossRef][PubMed]
    [Google Scholar]
  9. Tsai V, Pritzker BB, Diaz MH, Winchell JM, Hicks LA et al. Cluster of macrolide-resistant Mycoplasma pneumoniae infections in Illinois in 2012. J Clin Microbiol 2013; 51:3889–3892 [CrossRef][PubMed]
    [Google Scholar]
  10. Ferguson GD, Gadsby NJ, Henderson SS, Hardie A, Kalima P et al. Clinical outcomes and macrolide resistance in Mycoplasma pneumoniae infection in Scotland, UK. J Med Microbiol 2013; 62:1876–1882 [CrossRef][PubMed]
    [Google Scholar]
  11. Gullsby K, Bondeson K. No detection of macrolide-resistant Mycoplasma pneumoniae from Swedish patients, 1996-2013. Infect Ecol Epidemiol 2016; 6:31374 [CrossRef][PubMed]
    [Google Scholar]
  12. Kogoj R, Mrvic T, Praprotnik M, Kese D. Prevalence, genotyping and macrolide resistance of Mycoplasma pneumoniae among isolates of patients with respiratory tract infections, Central Slovenia, 2006 to 2014. Euro Surveill 2015; 20: [CrossRef][PubMed]
    [Google Scholar]
  13. Miyashita N, Kawai Y, Tanaka T, Akaike H, Teranishi H et al. Diagnostic sensitivity of a rapid antigen test for the detection of Mycoplasma pneumoniae: comparison with real-time PCR. J Infect Chemother 2015; 21:473–475 [CrossRef][PubMed]
    [Google Scholar]
  14. Liu Y, Ye X, Zhang H, Wu Z, Xu X. Rapid detection of Mycoplasma pneumoniae and its macrolide-resistance mutation by Cycleave PCR. Diagn Microbiol Infect Dis 2014; 78:333–337 [CrossRef][PubMed]
    [Google Scholar]
  15. Suzuki Y, Seto J, Shimotai Y, Ikeda T, Yahagi K et al. Development of an endpoint genotyping assay to detect the Mycoplasma pneumoniae 23S rRNA gene and distinguish the existence of macrolide resistance-associated mutations at position 2063. J Microbiol Methods 2016; 131:130–134 [CrossRef][PubMed]
    [Google Scholar]
  16. Wagner K, Imkamp F, Pires VP, Keller PM. Evaluation of Lightmix Mycoplasma macrolide assay for detection of macrolide-resistant Mycoplasma pneumoniae in pneumonia patients. Clin Microbiol Infect 2019; 25:383.e5–38383 [CrossRef][PubMed]
    [Google Scholar]
  17. Ito Y, Iwashima S, Hayano S, Nishio T, Shiozawa R et al. Rapid detection of the macrolide sensitivity of Pneumonia-causing Mycoplasma pneumoniae using quenching probe polymerase chain reaction (GENECUBE®). Mol Diagn Ther 2018; 22:737–747 [CrossRef][PubMed]
    [Google Scholar]
  18. Hayashi D, Akashi Y, Suzuki H, Shiigai M, Kanemoto K et al. Implementation of point-of-care molecular diagnostics for Mycoplasma pneumoniae ensures the correct antimicrobial prescription for pediatric pneumonia patients. Tohoku J Exp Med 2018; 246:225–231 [CrossRef][PubMed]
    [Google Scholar]
  19. Hida Y, Uemura K, Sugimoto H, Kawashima Y, Koyanagi N et al. Evaluation of performance of the geneCube assay for rapid molecular identification of Staphylococcus aureus and methicillin resistance in positive blood culture medium. PLoS One 2019; 14:e0219819 [CrossRef][PubMed]
    [Google Scholar]
  20. Hida Y, Hisada K, Shimada A, Yamashita M, Kimura H et al. Rapid detection of the Mycobacterium tuberculosis complex by use of quenching probe PCR (geneCube). J Clin Microbiol 2012; 50:3604–3608 [CrossRef][PubMed]
    [Google Scholar]
  21. Tani H, Miyata R, Ichikawa K, Morishita S, Kurata S et al. Universal quenching probe system: flexible, specific, and cost-effective real-time polymerase chain reaction method. Anal Chem 2009; 81:5678–5685 [CrossRef][PubMed]
    [Google Scholar]
  22. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother 2004; 48:4624–4630 [CrossRef][PubMed]
    [Google Scholar]
  23. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother 2008; 52:3542–3549 [CrossRef][PubMed]
    [Google Scholar]
  24. Li X, Atkinson TP, Hagood J, Makris C, Duffy LB et al. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J 2009; 28:693–696 [CrossRef][PubMed]
    [Google Scholar]
  25. Pereyre S, Guyot C, Renaudin H, Charron A, Bébéar C et al. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob Agents Chemother 2004; 48:460–465 [CrossRef][PubMed]
    [Google Scholar]
  26. Peuchant O, Ménard A, Renaudin H, Morozumi M, Ubukata K et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009; 64:52–58 [CrossRef][PubMed]
    [Google Scholar]
  27. Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother 2013; 57:4046–4049 [CrossRef][PubMed]
    [Google Scholar]
  28. Matsuda K, Narita M, Sera N, Maeda E, Yoshitomi H et al. Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan. BMC Infect Dis 2013; 13:591 [CrossRef][PubMed]
    [Google Scholar]
  29. Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012; 55:1642–1649 [CrossRef][PubMed]
    [Google Scholar]
  30. Ishiguro N, Koseki N, Kaiho M, Kikuta H, Togashi T et al. Regional differences in prevalence of macrolide resistance among pediatric Mycoplasma pneumoniae infections in Hokkaido, Japan. Jpn J Infect Dis 2016; 69:186–190 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001264
Loading
/content/journal/jmm/10.1099/jmm.0.001264
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error